An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index

References

• Dan N, Setua S, Kashyap VK, et al. Antibody-Drug Conjugates for Cancer Therapy: chemistry to Clinical Implications. Pharmaceuticals. 2018;11(2):66.
   Web of Science ®Google Scholar
• de Claro RA, McGinn K, Kwitkowski V, et al. Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18(21):5845–5849.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long‐term survival follow‐up from the randomized, Phase 3 INO‐VATE study. Cancer. 2019;125(14):2474–2487.
   PubMed Web of Science ®Google Scholar
• Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610–621.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, O’Donnell PH, Balar AV, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019;37(29):2592–2600.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155–165.
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, Ko CW, Lee JE, et al. Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. Oncologist. 2018;23(9):1103–1108.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791.
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697.
   PubMed Web of Science ®Google Scholar
• King HD, Dubowchik GM, Mastalerz H, et al. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J Med Chem. 2002;45(19):4336–4343.
   PubMed Web of Science ®Google Scholar
• Nejadmoghaddam MR, Minai-Tehrani A, Ghahremanzadeh R, Mahmoudi M, Dinarvand R, Zarnani AH. Antibody-Drug Conjugates: possibilities and Challenges. Avicenna J Med Biotechnol. 2019;11(1):3–23.
   PubMedGoogle Scholar
• Lyon RP, Bovee TD, Doronina SO, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33(7):733–735.
   PubMed Web of Science ®Google Scholar
• Fisher JE. Considerations for the Nonclinical Safety Evaluation of Antibody-Drug Conjugates. Antibodies. 2021;10:2.
   Web of Science ®Google Scholar
• Shen BQ, Xu K, Liu L, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184–189.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–337.
   PubMed Web of Science ®Google Scholar
• van der Lee MM, Groothuis PG, Ubink R, et al. The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers. Mol Cancer Ther. 2015;14(3):692–703.
   PubMed Web of Science ®Google Scholar
• Li JY, Perry SR, Muniz-Medina V, et al. HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. Cancer Cell. 2016;29(1):117–129.
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–9290.
   PubMed Web of Science ®Google Scholar
• Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10(5):328–343.
   PubMed Web of Science ®Google Scholar
• Guy DG, Uy GL. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. Curr Hematol Malig Rep. 2018;13(6):417–425.
   PubMed Web of Science ®Google Scholar
• Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 2009;100(9):1566–1572.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241–256.
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–5108.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang C, Li Z, et al. Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. MAbs. 2020;12(1):1699768.
   PubMed Web of Science ®Google Scholar
• Deslandes A. Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies. MAbs. 2014;6(4):859–870.
   PubMed Web of Science ®Google Scholar
• Mahmood I. Clinical Pharmacology of Antibody-Drug Conjugates. Antibodies. 2021;10(2):76.
   Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–712.
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17(20):6437–6447.
   PubMed Web of Science ®Google Scholar
• Mahalingaiah PK, Ciurlionis R, Durbin KR, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019;200:110–125.
   PubMed Web of Science ®Google Scholar
• Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8(4):659–671.
   PubMed Web of Science ®Google Scholar
• Zhao H, Gulesserian S, Malinao MC, et al. Mechanism for ADC-Induced Neutropenia: role of Neutrophils in Their Own Demise. Mol Cancer Ther. 2017;16(9):1866–1876.
   PubMed Web of Science ®Google Scholar
• Lee HE, Park KU, Yoo SB, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer. 2013;49(6):1448–1457.
   PubMed Web of Science ®Google Scholar
• Hunter FW, Barker HR, Lipert B, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2020;122(5):603–612.
   PubMed Web of Science ®Google Scholar
• Li F, Emmerton KK, Jonas M, et al. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res. 2016;76(9):2710–2719.
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–1046.
   PubMed Web of Science ®Google Scholar
• Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512–1522.
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Mayo MF, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70(6):2528–2537.
   PubMed Web of Science ®Google Scholar
• Erickson HK, Lewis Phillips GD, Leipold DD, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther. 2012;11(5):1133–1142.
   PubMed Web of Science ®Google Scholar
• Hamilton GS. Antibody-drug conjugates for cancer therapy: the technological and regulatory challenges of developing drug-biologic hybrids. Biologicals. 2015;43(5):318–332.
   PubMed Web of Science ®Google Scholar
• Hinrichs MJ, Dixit R. Antibody Drug Conjugates: nonclinical Safety Considerations. AAPS J. 2015;17(5):1055–1064.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Mundo EE, Zhang C, et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem. 2011;22(10):1994–2004.
   PubMed Web of Science ®Google Scholar